Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02068586 |
|
Recruitment Status :
Recruiting
First Posted : February 21, 2014
Last Update Posted : January 7, 2021
|
Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University
Collaborator:
Pfizer
Information provided by (Responsible Party):
Thomas Jefferson University ( Sidney Kimmel Cancer Center at Thomas Jefferson University )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 31, 2021 |
| Estimated Study Completion Date : | July 2022 |